Congratulations Ray Elliot, you're clearly more popular than the last guy. Too bad this was how we had to find out.
In contrast to Elliot's predecessor Jim Tobin, who saw shares of Boston Scientific
Elliot was supposed to be able to turn things around at Boston Scientific. But less than two years after he took the helm, he's jumping ship -- sort of, he'll remain on the board -- with shares down about 25%, despite a 45% increase in the S&P500.
Stock price aside, I wouldn't say that Elliot's tenure was a failure. He sold off nonessential units, like its neurovascular unit that went to Stryker
Elliot couldn't work the magic like he did at Zimmer Holdings
Elliot plans to stay on to help find his replacement. One person that won't be available for the job is Omar Ishrak, CEO of General Electric's health care systems business. He took the CEO job at Boston Scientific's rival Medtronic
Can a new CEO move the stock? Who knows. Boston Scientific remains a show-me company. My suggestion is to forget trying to grab the as-yet-elusive bottom, sacrifice some of the upward trend when it does finally turn around, and buy once it's proven it has some legs.
Until then, add Boston Scientific to My Watchlist.
Stryker is a Motley Fool Inside Value selection. The Fool owns shares of Medtronic, and Zimmer Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.